U.S. markets closed

Ascendis Pharma A/S (ASND)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
109.80+1.66 (+1.54%)
At close: 04:00PM EDT
109.14 -0.66 (-0.60%)
After hours: 04:11PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close108.14
Bid109.19 x 800
Ask109.90 x 1100
Day's Range107.18 - 110.54
52 Week Range61.58 - 134.52
Avg. Volume267,242
Market Cap6.275B
Beta (5Y Monthly)0.55
PE Ratio (TTM)N/A
EPS (TTM)-10.97
Earnings DateMay 09, 2023 - May 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.39
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ASND

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ascendis Pharma A/S
    NKTR: Lowering target price to $0.93NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.928000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Zacks

    Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last?

    Omega Therapeutics, Inc. (OMGA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • GlobeNewswire

    Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference

    COPENHAGEN, Denmark, March 10, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15. Details: EventOppenheimer 33rd Annual Healthcare ConferenceLocationVirtualDateWednesday, March 15, 2023Time12:00-12:30 p.m. Eastern Time / 9:00-9:

  • Insider Monkey

    Ascendis Pharma A/S (NASDAQ:ASND) Q4 2022 Earnings Call Transcript

    Ascendis Pharma A/S (NASDAQ:ASND) Q4 2022 Earnings Call Transcript February 16, 2023 Operator: Good day, and thank you for standing by. Welcome to the Ascendis Pharma Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session . Please […]